Glucose exerts powerful effects on hepatocyte gene transcription by mechanisms that are incompletely understood. c-Myc regulates hepatic glucose metabolism by increasing glycolytic enzyme gene transcription while concomitantly decreasing gluconeogenic and ketogenic enzyme gene expression. However, the molecular mechanisms by which c-Myc exerts these effects is not known. In this study, the glucose-mediated induction of L-type pyruvate kinase and glucose 6-phosphatase mRNA levels was diminished by maneuvers involving recombinant adenoviral vectors that interfere with (i) c-Myc protein levels by antisense expression or (ii) c-Myc function through a dominant-negative Max protein. These results were obtained using both HL1C rat hepatoma cells and primary rat hepatocytes. Further, a decrease in c-Myc abundance reduced glucose production in HL1C cells, presumably by decreasing glucose 6-phosphatase activity. The repression of hormone-activated phosphoenolpyruvate carboxykinase gene transcription by glucose was not affected by a reduction in c-Myc levels. The basal mRNA levels for L-pyruvate kinase and glucose 6-phosphatase were not altered to any significant degree by adenoviral treatment. Furthermore, adenoviral overexpression of the c-Myc protein induced glucose 6-phosphatase mRNA in the absence of glucose stimulation. We conclude that multiple mechanisms exist to communicate the glucose-derived signal, and that c-Myc has a key role in the hepatic glucose signaling pathway.
Introduction
Insulin and glucose act jointly to influence glucose homeostasis by altering hepatic gene expression patterns. Insulin increases glucokinase (GK) 1 gene transcription and protein levels in hepatocytes (1) . The phosphorylation of glucose by GK leads to increased glucose flux and metabolism, generating signaling metabolites that modify the gene expression profile of the liver (2) . For example, the L-pyruvate kinase (L-PK) and glucose 6-phosphatase (G-6-Pase) genes (encoding key glycolytic and gluconeogenic enzymes, respectively) are stimulated by increases in hepatic glucose metabolism (3) (4) (5) .
Conversely, glucose metabolism can also negatively regulate gene transcription, exemplified by the repression of hormone-activated phosphoenolpyruvate carboxykinase gene promoter activity [PEPCK; refs. (6, 7) ]. Although glucose metabolism modulates the gene expression patterns of key glycolytic and gluconeogenic enzymes, the signaling mechanisms and coordinating transcription factors involved are not fully characterized.
One transcription factor that is a candidate for establishing hepatic glucose-dependent gene expression patterns is the basic, helix-loop-helix leucine-zipper (bHLH-LZ) transcription factor c-Myc (8, 9) . The Myc family of proteins (e.g., c-, N-, L-Myc, USF, Max, Mad, etc.) participates in the control of proliferation, growth and differentiation, apoptosis, and metabolism (10, 11) . c-Myc binds DNA by interacting with the E-box sequence CACGTG (and other related non-canonical sites), as a heterodimer with Max, another bHLH-LZ protein. The Myc/Max heterodimer activates or represses transcription depending on the target gene (11, 12) . Sequences very similar to the E-box are present in the carbohydrate response elements of the L-pyruvate kinase and S14 gene promoters (3, 13, 14) .
A three-fold overexpression of c-Myc in the liver of transgenic mice, driven by the PEPCK promoter, increases hepatic glucose metabolism and storage, presumably due to the substantial rise in GK activity (no increase in HK I activity was detected) ref. (9) .
The expression of glucose transporter 2 (GLUT2), L-PK, and 6-phosphofructo-2kinase/fructose-2,6-bisphosphatase (PFK2) all increase, as well as liver glycogen content, indicating that hepatic glucose metabolism is enhanced. Furthermore, in c-Myc overexpressing animals treated with streptozotocin, and therefore lacking insulin, glucose and ketone production decrease (8) . These changes are accompanied by a decrease in mRNA levels for PEPCK and carnitine palmitoyl transferase (CPT) I and II.
Importantly, this hepatic elevation in c-Myc protein levels in vivo is sufficient to nearly normalize fasting serum glucose levels and thus prevent streptozotocin-induced diabetes (8) . Taken together, these results are consistent with c-Myc playing a major role in the control of hepatic glucose metabolism in vivo. However, the molecular mechanisms mediating these changes have not been elucidated.
In the present study, we decreased the abundance of the c-Myc protein using a recombinant adenovirus that expresses antisense c-myc RNA (AdCMV-ASmyc) to test whether this transcription factor is required for glucose-regulated gene expression in hepatocytes. Cells treated with AdCMV-ASmyc had 50% less c-Myc protein than cells treated with an equal amount of a control adenovirus. This reduction in c-Myc was sufficient to block the glucose-stimulated expression of glucose-responsive genes in both HL1C rat hepatoma cells and rat primary hepatocytes. Further, a recombinant adenovirus expressing a dominant-negative Max protein mimicked the effect of AdCMV-ASmyc.
Reducing c-Myc levels decreased glucose production in HL1C hepatoma cells, presumably by decreasing G-6-Pase activity. In addition, treatment with a recombinant adenovirus that expresses c-Myc increased G-6-Pase gene expression when cells were incubated in 2 mM glucose, partially mimicking the effect of 20 mM glucose. Finally, repression of hormone-activated PEPCK gene promoter activity by glucose was not alleviated by a reduction in c-Myc protein, suggesting multiple pathways for glucose signaling.
Experimental Procedures
Cell Culture-The HL1C rat hepatoma cell line contains the PEPCK promoter sequence (from -2100 to +69, relative to the transcription start site) ligated to the chloramphenicol acetyltransferase (CAT) reporter gene (15) . The culture of HL1C cells, and the assay for measurement of CAT activity have been described (16, 17) .
Primary Hepatocytes-Hepatocytes from overnight-fasted or ad libitum fed male Wistar rats (250-350g) were isolated using the collagenase perfusion method as described previously (18) . Cells were allowed to attach for 3hr in hepatocyte medium (glucose-free DMEM [Gibco] supplemented with 15 mM HEPES, 33 µM biotin, 40 µM phenol red, 1 mM sodium pyruvate, 17 µM pantothenate, 14 mM sodium bicarbonate, 5 x 10 4 U/L penicillin, 5 x 10 4 µg/L streptomycin, 4 mM L-glutamine, 50 mg/L gentamicin, 2.5 mg/L fungizone) plus 5.5 mM glucose, 10% FBS, 0.5 µM dexamethasone and 10 nM insulin.
Recombinant adenovirus was added and allowed to attach to the cells for one hour. The medium containing adenovirus was aspirated and cells were then incubated for 24 hr in fresh hepatocyte medium supplemented with 0.2% BSA and 2 mM glucose. Thus, insulin and FBS were removed from the media for 24 hr, and cells were kept in 2 mM glucose for 24 hr prior to overnight treatment with 20 mM glucose. Preparation of hepatocytes from ad libitum fed rats was as described above for fasted rats, with the exception that the cells were exposed to 10 nM insulin and 5% FBS along with 2 mM glucose for 24 hr after the 3 hr attachment period. The cells were then washed three times with Dulbecco's PBS, and re-incubated in hepatocyte medium (without insulin or FBS) for treatment with 2 or 20 mM glucose overnight.
Construction, Preparation and Use of Recombinant Adenoviruses-A 500 bp cDNA
generated by RT-PCR, and corresponding to nucleotides 2169-2569 (the entire exon 1) and 2570-2670 (100 bp of exon 2) of the rat c-myc gene (GenBank Accession: Y00396) was subcloned in a 3'-5' orientation into the adenovirus vector pACCMV.pLpA. The insert was sequenced using the dideoxy nucleotide method for verification of correct orientation and sequence and subsequently was used to generate a recombinant adenovirus (AdCMV-ASmyc) as previously described (19) . The resulting virus was plaque-purified and used to treat 50% confluent HL1C cells in 10 cm dishes at varying titers. Primary hepatocytes at 80% confluence were treated in 60 mm collagen coated dishes as described in the figure legends. A virus containing the bacterial β-galactosidase gene (AdCMV-βGal) was used as a control (20) . After a 60-90 min incubation with adenovirus, the cells were placed in fresh medium, and harvested 40 hr later.
RNA Isolation-Total RNA was isolated from HL1C cells and primary hepatocytes using TRI-reagent (Molecular Research Center) according to the manufacturer's protocol.
Semi-quantitative RT-PCR Assay-
The reverse transcription (RT) reaction contained 1 µg total RNA, 1 µl random primer (50 µM, Applied Biosystems), 1X reverse transcriptase buffer, 10 U MMLV reverse transcriptase (Promega) in a total volume of 20 µl. The RNA and primer were annealed by heating to 72°C and slowly cooled to room temperature before the reverse transcriptase was added and the reaction was allowed to proceed at 42°C for 1 h. The RT reaction was then diluted to 100 µl with RNase-free water. The polymerase chain reaction contained 1X Taq polymerase buffer (Promega), The number of cycles used in the PCR was determined empirically for each primer pair to be within the linear range of amplification. In addition, the amount of RNA used for the RT reaction (1 µg) was determined to be in the linear response range when comparing RNA input to PCR product abundance (data not shown). Furthermore, the sequence of the PCR products was verified by dideoxy sequencing (Sequenase). The PCR reaction was as follows: 15 min at 95°C, followed by 25 to 30 cycles of 30 sec at 95°C, 30 sec at 62°C, and 30 sec at 72°C, followed by a 5 min extension at 72°C. PCR products were separated on 1.8% agarose gels and stained with ethidium bromide. The abundance of the PCR products was quantitated using a Kodak EDAS 290 gel documentation system and NIH/Scion image software. We have validated this assay by finding that the relative abundance of cyclophilin mRNA was linear from 0.1 to 1.0 µg of input RNA (r=0.995) 2 .
Thus, this semi-quantitative RT-PCR assay has a high degree of precision and results in a linear response with respect to input RNA concentrations over at least one order of magnitude.
Preparation of Nuclear Extracts-Nuclear extracts were prepared as a modification of the procedure described previously (21). The protein concentration was determined using the BCA assay (Pierce Chemical Company) with bovine serum albumin as the standard. anti-tubulin, 1:5000, a gift from Dr. Kevin Brown) was incubated at room temperature with the membrane for four hours with continuous shaking. The membranes were then washed three times for five minutes each with TBS. After washing, the secondary antibody (anti-rabbit coupled to horse radish peroxidase, Kirkegaard & Perry Laboratories, Inc.) was applied at 1:20,000 and allowed to bind for two hours at room temperature with continuous shaking. The membranes were again washed three times for five minutes. After the third wash, the membranes were exposed to the SuperSignal chemiluminescent reagent (Pierce) for one minute. Equal protein loading was confirmed by either ponceau S (Sigma) staining of the PVDF membrane after transfer, or by immunoblotting for the abundance of tubulin. Densitometry was performed using Scion image software (NIH). Glucose Production Assay-HL1C cells at 50% confluence were treated with AdCMV-GKL and either AdCMV-βGal or AdCMV-ASmyc. Twenty-four hours after viral transduction, the cells were treated overnight with 2 or 20 mM glucose. The media was then replaced with glucose-free Dulbecco's modified essential medium and glucose production measured essentially as described using a glucose assay kit (Sigma 510-A) (22, 23) . The medium used for measurement of glucose production was modified slightly to include 1 mM glycerol, 2 mM pyruvate, and 20 mM lactate. The pH of the medium was 7.4 and did not contain phenol red.
Transient Transfection and Dual Luciferase Assay-Transfections

Statistical Analysis-All results are expressed as means + standard errors (SE). Data
analysis was performed using the statistics module of Microsoft Excel Version 9.0 (Microsoft Corp.). Statistical significance in the form of a two-tailed t-test was rejected at p > 0.05.
Results
AdCMV-ASmyc produces an antisense c-myc mRNA A recombinant adenovirus
(AdCMV-ASmyc) was constructed to produce an antisense c-myc mRNA. HL1C rat hepatoma cells were transduced with AdCMV-ASmyc or a control adenovirus, AdCMV-βGal (20) , and the effect of increasing the moi from 12.5 to 50 pfu/cell on mRNA abundance was assessed by RT-PCR ( Fig. 1 ). Elevation of the viral titer augmented the steady state mRNA levels of antisense c-myc and β-galactosidase. 
AdCMV-ASmyc decreases c-Myc protein levels and transcriptional activity
AdCMV-ASmyc blunts the glucose-stimulated expression of the L-pyruvate kinase and G-6-Pase genes
Glucose metabolism generates a signal that potently affects hepatic gene transcription, and c-Myc has been implicated in the control of glucose-regulated gene expression (2, 9, 25) . Therefore, HL1C cells were transduced with AdCMV-ASmyc to determine whether the glucose-mediated induction of the L-PK or G-6-Pase genes requires the full complement of endogenous c-Myc protein expression. HL1C cells do not express GK, a feature shared with many hepatoma cell lines (26) . Thus, GK was expressed via a recombinant adenovirus to increase glucose flux and metabolism. HL1C cells expressing GK, and treated with 20 mM glucose, display a 2-and 4-fold increase in the mRNAs for the L-pyruvate kinase and G-6-Pase genes, respectively when compared to control cells (Fig.3 ). These observations are consistent with previous findings wherein glucose decreased PEPCK gene promoter activity in the same cell system (6) . Treatment with AdCMV-ASmyc blunted the glucose-mediated increase in the mRNA levels of L-PK and G-6-Pase in a concentration dependent manner in HL1C cells, while treatment with AdCMV-βGal over the same concentration range had no significant effect on the expression of these genes (Fig. 3 ).
After observing these effects in HL1C cells, we carried out similar experiments in primary hepatocytes isolated from overnight-fasted rats. In this system, insulin levels, and thus GK levels, are quite low. To provide an increased glucose flux, GK was expressed by adenoviral transduction, which allows us to effectively separate the glucosesignaling pathway from the insulin-signaling pathway. Subsequent addition of 20 mM glucose to these cells increased G-6-Pase gene expression by 4-fold when compared to incubation in 2 mM glucose. However, treatment with AdCMV-ASmyc blocked the glucose-mediated induction, while AdCMV-βGal had no significant effect ( Fig. 4 A) . L-PK gene expression was also repressed in rat primary hepatocytes in the presence of AdCMV-ASmyc, although not as dramatically as in HL1C hepatoma cells, as it did not reach statistical significance (p=0.07) ( Fig 4B) . Taken together, these data demonstrate that a 50% reduction in c-Myc protein levels is sufficient to inhibit glucose-regulated gene expression in HL1C rat hepatoma cells and rat primary hepatocytes.
Expression of a dominant-negative Max protein inhibits the glucose-mediated induction of G-6-Pase
We determined whether disabling the ability of the Myc-Max transcription complex to bind DNA had the same effect as reducing c-Myc protein levels on the glucose-mediated induction of the G-6-Pase gene. In these experiments, primary hepatocytes from fed rats were used to take advantage of high endogenous levels of glucokinase, thereby alleviating the need for adenoviral replacement of the enzyme. This cell culture system displays robust glucose-stimulated gene expression similar to our previous model systems described above and is the predominant system used in the study of glucose-mediated gene expression (3, 13) . We note that AdCMV-ASmyc also decreases the abundance of G-6-Pase mRNA is this system (data not shown). An adenovirus expressing a dominant negative, flag-tagged Max protein (AdCMV-AMax), wherein the basic region of Max is replaced with an acidic domain (27) , was used to evaluate the necessity of the heterodimer complex. The AMax protein heterodimerizes with c-Myc generating a protein-protein interaction that is thermodynamically more stable than the association of c-Myc with endogenous Max, and the AMax-Myc complex is unable to bind to (27) . Adenoviral-mediated expression of the AMax protein in primary rat hepatocytes inhibited the induction of G-6-Pase gene expression by glucose metabolism (Fig. 5 ). We conclude that a functional Myc-Max complex is necessary for maximal glucose-stimulated expression of the G-6-Pase gene.
AdCMV-ASmyc blocks glucose production in HL1C rat hepatoma cells-Since
AdCMV-ASmyc blunts the glucose-mediated expression of pyruvate kinase and G-6-Pase, we determined if treatment with this adenovirus had an affect on cellular metabolism. We saw no effect on lactate production (data not shown), perhaps because the effect of AdCMV-ASmyc on PK mRNA was relatively small compared to that of G-6-Pase ( Figs. 3 and 4 ). G-6-Pase catalyzes the removal of the phosphate group from glucose 6-phosphate as the terminal step in gluconeogenesis. We sought to determine whether reducing c-Myc levels would interfere with the ability of HL1C rat hepatoma cells to produce glucose. HL1C cells transduced with AdCMV-GKL and either AdCMV-βGal or AdCMV-ASmyc were used for this purpose. Glycerol was added to the medium as a gluconeogenic substrate to bypass the PEPCK reaction (conversion of oxaloacetate to phosphoenolpyruvate) since the gene encoding this enzyme is known to be repressed by glucose metabolism (6, 7) . Under these conditions, glycerol enters the gluconeogenic pathway at the triose level, and glucose production should increase with increasing G-6-Pase activity despite a reduction in PEPCK activity. The cells expressing AdCMV-ASmyc and treated with 20mM glucose (to stimulate G-6-Pase gene expression) produced approximately 50% less glucose than did cells expressing AdCMV-βGal and treated with same concentration of glucose ( Figure 6 ). Therefore, reducing c-Myc abundance reduces the glucose production capacity of HL1C cells.
Reducing c-Myc protein levels in HL1C rat hepatoma cells does not affect unstimulated mRNA levels of either the L-PK or G-6-Pase genes One possible
mechanism by which AdCMV-ASmyc may influence gene expression is to alter basal transcription. Thus, we examined the effect of reducing c-Myc protein levels on L-PK and G-6-Pase mRNA levels in HL1C cells after an overnight culture in 2mM glucose (Fig 7) . We found that the mRNA abundance of each of these genes was not significantly different in cells transduced with AdCMV-βGal when compared to cells transduced with the same moi of AdCMV-ASmyc. These data demonstrate that reducing c-Myc protein levels does not affect unstimulated mRNA levels of the L-PK and G-6-Pase genes and suggests that c-Myc participates specifically in the glucose-stimulation of gene transcription. AdCMV-c-Myc (Fig.8A) . The c-Myc treatment produced a 50% increase in G-6-Pase gene expression from cells incubated in 2 mM glucose ( Fig. 8B ). However, treatment with AdCMV-βGal at the same moi did not alter expression of the gene. Although the increase in gene expression seen in this experiment is not as dramatic as that induced by 20 mM glucose, it is further evidence that c-Myc regulates the expression of the G-6-Pase gene.
Overexpressing c-Myc via a recombinant adenovirus increases the mRNA levels of G-
6-Pase at a non-stimulating glucose concentration
Reducing c-Myc levels does not affect the glucose-mediated repression of the hormoneactivated PEPCK promoter Glucocorticoids and glucagon, via the cyclic AMP signaling
pathway, activate the PEPCK gene, leading to hepatic glucose production that maintains plasma euglycemia in the absence of ingested fuel substrates (30) . Glucose metabolism provides a signal that leads to transcriptional repression of the PEPCK gene in HL1C cells (6, 7) . We sought to determine whether diminishing c-Myc protein levels alleviated the glucose-mediated repression of PEPCK promoter activity. HL1C cells contain the PEPCK promoter (-2100 to +69) sequence linked to the chloramphenicol acetyltransferase (CAT) reporter gene (15) . Treating HL1C cells with dexamethasone and 8-(4-chlorophenyl-thio)cAMP produces a 50-fold induction of CAT activity. In the presence of adenovirally-expressed GK and 20mM glucose, this activity is reduced by 80% (6) . Depleting c-Myc levels did not reverse the glucose-dependent repression of CAT activity, nor did the control virus lessen the glucose-dependent effects (Fig 9) . Surprisingly, the highest moi of AdCMV-ASmyc further repressed promoter activity significantly, while the same moi of AdCMV-βGal did not. These results demonstrate that c-Myc is not necessary for the glucose-mediated repression of the hormone-activated PEPCK promoter, and suggest the existence of multiple glucose signaling pathways.
Discussion
Glucose is a strong regulator of hepatic gene transcription (2, 25) . Increased glucose metabolism coordinately increases the expression of glycolytic and lipogenic enzyme genes, and decreases the expression of ketogenic and gluconeogenic enzyme genes. c-Myc regulates hepatic glucose metabolism in vivo by increasing the expression and activity of glycolytic enzymes and exerting the reverse effect on those of glucose and ketone production (8, 9) . In this study, we demonstrate several important observations regarding the role of c-Myc in hepatic glucose metabolism: 1) maneuvers that result in a reduction of c-Myc protein levels were able to blunt the glucose-stimulated induction of G-6-Pase and mRNAs in both HL1C rat hepatoma cells and rat primary hepatocytes; A three-fold overexpression of c-Myc driven by the PEPCK promoter in the liver of transgenic mice increases GK, PFK2, and L-PK gene expression despite insulin deprivation by streptozotocin treatment (8) . These changes in gene expression are sufficient to increase hepatic glucose flux and suppress glucose output from the liver, thereby protecting the animals from overt diabetes. In the present study, a 50% reduction of c-Myc in rat hepatoma cells and primary hepatocytes blunts the ability of glucose to stimulate expression of the L-PK and glucose 6-phosphastase genes (Figs. 3 & 4 ). In addition, overexpression of c-Myc partially mimics the glucose effect in primary hepatocytes (Fig. 8) . Therefore, our observations are consistent with the transgenic findings. Together, these data indicate that c-Myc is important for controlling hepatic gene expression patterns, and is a key factor in the regulation of gene expression by glucose.
In this study, a dominant-negative Max protein (AdCMV-AMax) was expressed by adenovirus to test whether a Myc-Max heterodimer is required for the glucose-activation of G-6-Pase. Introduction of the AMax protein, which functions as a dominant-negative by allowing heterodimerization but not DNA binding, prevented the glucose-induced rise in G-6-Pase mRNA levels (Fig. 5 ). This observation suggests that a functional Myc-Max heterodimer is required for the stimulatory glucose effect. How this complex regulates gene transcription upon stimulation with glucose is unknown.
Glucose metabolism increases G-6-Pase mRNA and protein levels (5, 31, 32) . Since reducing c-Myc levels blunted the ability of glucose to stimulate G6Pase mRNA levels ( Figs. 3 and 4) , we determined whether this affected the ability of the cell to produce and release glucose. We found that decreasing c-Myc levels diminished the glucose production of HL1C cells (Fig. 6 ). Thus, glucose production can be modified by altering levels of c-Myc.
The physiological significance of glucose exerting a stimulatory effect on G-6-Pase and a repressive effect on PEPCK, both gluconeogenic enzymes, has never been fully understood (6, 7) . There are several possible explanations for the paradoxical glucosemediated induction of G-6-Pase. One possibility is that a glucose-mediated elevation in G-6-Pase activity serves as a feedback mechanism to decrease the signal intensity provided by increased glucose flux and metabolism. By this view, the glucose-stimulated increase in G-6-Pase would decrease the abundance of glucose 6-phosphate and other potential signaling metabolites, particularly after the suppressive effect of insulin (33) has diminished towards the end of the fed state. This would limit the extent of glucose signaling and potentiate a transition to the fasted state. One consequence of this arrangement is that an overexpression of G-6-Pase, as seen in Type II diabetes, would lead to a decreased ability of c-Myc and other factors to coordinately regulate hepatic metabolic enzyme genes, and may partially explain the dysregualted hepatic glucose metabolism seen in Type II diabetes (34) .
The glucose-mediated induction of the L-PK gene, and presumably other glucoseresponsive genes, requires GK expression and glucose metabolism in primary hepatocytes, rat hepatomas and in vivo 2 (31, 35) . Further, the repression of hormoneactivated PEPCK promoter activity is dependent upon the metabolism of glucose, and occurs in the absence of insulin provided GK is expressed (6) . Thus, glucose downregulates its own production in the liver via a negative feedback mechanism at the same time that it promotes glucose utilization. However it is not known if the coordinating mechanisms for increasing gene transcription are the same for the repression of gene transcription. In the present study, we found that reducing c-Myc levels had no effect on the glucose-repression of the PEPCK promoter ( Fig. 9 ), suggesting that multiple glucose-signaling pathways exist.
Glucose regulates gene transcription by acting through specific promoter elements, designated carbohydrate response elements, or ChoREs (3, 25) . These elements were first described in the context of the L-PK gene promoter, and require a bHLH-LZ family member to fully stimulate the gene's response to carbohydrate (3, 36) . The L-PK ChoRE contains two non-canonical E-boxes separated by five base pairs. The E-boxes described for the glucose-response element of the L-PK gene promoter are different from the c-Myc family canonical E-box by a single nucleotide (3, 13) . Also, a conserved carbohydrate response element consisting of "half E-boxes" (CACG), and documented in the S 14 gene promoter, is necessary and sufficient to regulate transcription in response to glucose (37) . Establishment of the ChoRE lead to the detection, by electrophoretic mobility shift assay, of a novel ChoRE-binding factor (ChoRF) that still awaits complete characterization (36, 37) .
Another candidate for activation of glucose-responsive genes was provided by the discovery of a novel transcription factor, termed carbohydrate response element-binding protein (ChREBP), that regulates hepatic L-PK gene expression upon refeeding in rats (38, 39) . ChREBP, another bHLH/leucine zipper protein, is regulated by phosphorylation status, which controls its nuclear localization and DNA binding capabilities (39) . In the presence of glucose, ChREBP is de-phosphorylated, migrates to the nucleus, and participates in controlling glucose-dependent L-PK gene expression, possibly by binding to the E-box motif present in the L-PK promoter (38, 39) . Interestingly, the Williams-Beuren syndrome critical region 14 protein (WBSCR14), which is the human homologue of rat ChREBP, heterodimerizes with Mlx, a member of the c-myc family of transcription factors (40) Representative inverse images of the PCR products on agarose gels are displayed (insets). 
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